Notes
The study was funded by and is part of an alliance between Merck KGaA and Pfizer, Inc., NY, USA.
Reference
Bullement A, et al. Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics-Open : 24 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-018-0115-y
Rights and permissions
About this article
Cite this article
Avelumab promising cost-effective option for Merkel cell carcinoma. PharmacoEcon Outcomes News 821, 8 (2019). https://doi.org/10.1007/s40274-019-5625-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5625-z